Moleculin Biotech, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MBRX | ATORX.ST | PCSA | APVO | MBIO | PPBT | |
|---|---|---|---|---|---|---|
| Market cap | 8.62M | 38.89M | 5.41M | 2.90M | 3.14M | 1.98M |
| P/E (TTM) | 0.0 | — | — | 0.0 | — | — |
| Forward P/E | -0.1 | -0.1 | -0.5 | -0.1 | -1.2 | -1.2 |
| Price/book | 0.3 | 0.3 | -17.0 | 0.3 | 0.4 | 0.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −96.52% | −99.41% | −77.18% | −94.72% | −69.02% | −85.52% |
| Today | +1.93% | +1.87% | −0.26% | +0.74% | +1.07% | +2.97% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All MBRX news ›Moleculin Biotech Completes Dosing in Phase 2/3 MIRACLE Trial for AnnAraC
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends. Moleculin Biotech Completes Dosing in Phase 2/3 MIRACLE Trial for…
Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027
Milestone underscores execution of pivotal Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute my... Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive…
Moleculin Biotech, Inc. Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin Miracle Trial
Moleculin Biotech, Inc. announced that it has released the next segment on its CEO Corner. In this episode of CEO Corner, Moleculin Biotech Chairman and CEO Walter Klemp discusses the progress of the... announced that it has released the…
Certain Restricted Stock Units of Moleculin Biotech, Inc. are subject to a Lock-Up Agreement Ending on 3-OCT-2026.
These Restricted Stock Units will be under lockup for 60 days starting from... Certain Restricted Stock Units of Moleculin Biotech, Inc are subject to a Lock-Up Agreement Ending on 3-O
Moleculin Biotech, Inc. Completes and Closes Enrollment in Part A of Its Pivotal Phase 2/3 Miracle Trial Evaluating Annamycin in Combination with Cytarabine
Moleculin Biotech, Inc. announced that it has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine for the treatment of... announced that it has completed and…
Stacy Malaker Advances Mucin Research in Cancer Fight
Stacy Malaker isn't married to her work, but she did discourage her graduate students from texting any interesting tidbits about the lab during her honeymoon over the summer. "I saw one message, and I didn't respond," said Malaker, an…
Cash flow from investing activities of MOLECULIN BIOTECH INC – GETTEX:A42P30
TradingView Cash flow from investing activities of MOLECULIN BIOTECH INC
Moleculin Announces Reverse Stock Split
The Manila Times Moleculin Announces Reverse Stock Split HOUSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), today announced that it filed an amendment to its amended and…
Moleculin Biotech (NASDAQ:MBRX) Stock to Reverse Split on Tuesday, October 20th
Posted by Mitch Edgeman on Oct 17th, 2026 Shares of Moleculin Biotech, Inc. (NASDAQ:MBRX – Free Report) are scheduled to reverse split on Tuesday, October 20th. The 1-20 reverse split was recently announced. The number of shares owned by…
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
Moleculin Biotech (MBRX) will participate in the Advances in Oncology Panel at the 2026 Maxim Growth Summit on October 14, 2026. Chairman and CEO Walter Klemp will present from 9:00 to 10:00 a.m. ET at the Hard Rock Hotel NYC. HOUSTON,…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com7
- globenewswire.com2
- manilatimes.net2
- stocktitan.net2
- markets.businessinsider.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 16 articles, not a forecast.